Free Trial

Cytek Biosciences (CTKB) News Today

$6.02
+0.06 (+1.01%)
(As of 05/21/2024 ET)
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $5.96
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $5.96
Cytek Biosciences (NASDAQ:CTKB) PT Lowered to $8.50
Piper Sandler Cuts Cytek Biosciences (NASDAQ:CTKB) Price Target to $8.50
Piper Sandler decreased their price target on shares of Cytek Biosciences from $10.00 to $8.50 and set an "overweight" rating on the stock in a report on Monday.
Cytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) to Release Quarterly Earnings on Wednesday
Cytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591278)
Cytek Biosciences (NASDAQ:CTKB) Trading 6.6% Higher
Cytek Biosciences (NASDAQ:CTKB) Trading Up 6.6%
New York State Common Retirement Fund Grows Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)
New York State Common Retirement Fund raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,947,986 shares of
Insider Selling: Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells 20,000 Shares of Stock
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the stock in a transaction on Friday, April 19th. The stock was sold at an average price of $5.87, for a total value of $117,400.00. Following the sale, the chief technology officer now directly owns 5,988,502 shares in the company, valued at $35,152,506.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Short Interest in Cytek Biosciences, Inc. (NASDAQ:CTKB) Increases By 16.9%
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 9,950,000 shares, a growth of 16.9% from the March 15th total of 8,510,000 shares. Approximately 8.4% of the company's shares are short sold. Based on an average daily trading volume, of 723,300 shares, the short-interest ratio is presently 13.8 days.
Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells $13,300.00 in Stock
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 1,900 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $7.00, for a total transaction of $13,300.00. Following the completion of the sale, the chief technology officer now owns 6,008,502 shares of the company's stock, valued at approximately $42,059,514. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. increased its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,079,421 shares of the company's stock a
Cytek Biosciences (NASDAQ:CTKB) Trading 5% Higher
Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%
Short Interest in Cytek Biosciences, Inc. (NASDAQ:CTKB) Rises By 9.2%
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 8,510,000 shares, an increase of 9.2% from the February 29th total of 7,790,000 shares. Currently, 7.1% of the company's shares are short sold. Based on an average trading volume of 731,300 shares, the days-to-cover ratio is currently 11.6 days.
Cytek Biosciences (NASDAQ:CTKB) Stock Price Down 3.3%
Cytek Biosciences (NASDAQ:CTKB) Shares Down 3.3%
Cytek Biosciences (NASDAQ:CTKB) Shares Down 4.8% After Insider Selling
Cytek Biosciences (NASDAQ:CTKB) Shares Down 4.8% Following Insider Selling
Cytek Biosciences, Inc. (NASDAQ:CTKB) CTO Sells $135,400.00 in Stock
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $6.77, for a total value of $135,400.00. Following the completion of the transaction, the chief technology officer now directly owns 6,030,402 shares in the company, valued at $40,825,821.54. The sale was disclosed in a filing with the SEC, which is available through this link.
CTKB Mar 2024 5.000 put
RA Capital Management L.P. Reduces Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)
RA Capital Management L.P. decreased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 44.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,809,404 shares of the company's stock afte
Piper Sandler Cuts Cytek Biosciences (NASDAQ:CTKB) Price Target to $10.00
Piper Sandler lowered their price objective on shares of Cytek Biosciences from $11.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday.
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up Following Analyst Upgrade
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up on Analyst Upgrade
Connor Clark & Lunn Investment Management Ltd. Takes $1.26 Million Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Connor Clark & Lunn Investment Management Ltd. bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 228,395 shares of the company's stock, valued at app
Cytek Biosciences Reports Full Year 2023 Earnings
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up After Analyst Upgrade
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up After Analyst Upgrade
Get Cytek Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.

Everybody laughed when he recommended Netflix (Ad)

"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.

Click here to see how it could become the No. 1 investment of the next decade.

CTKB Media Mentions By Week

CTKB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTKB
News Sentiment

0.22

0.44

Average
Medical
News Sentiment

CTKB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTKB Articles
This Week

5

2

CTKB Articles
Average Week

Get Cytek Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CTKB) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners